Several PHD inhibitors are in phase III clinical trials for anaemia related to chronic kidney disease [120], and crystallographic studies predict that they bind to the active site metal and 2-OG to inhibit catalytic activity [121]. This evidence concerns the gene PDC and chronic kidney disease.